2024 perioperative management glp-1 receptor agonists anesthesia of patients on agonists: Risks, recommendations, and future directions—A narrative review Perioperative anesthesia management of GLP-1

Description

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

To support our research and testing, we may earn a commission if you sign up or purchase through certain links on this page at no additional cost to you

Although most of the studies reported an association between GLP-1 RA and increased residual gastric contents, evidence linking these medications to a statistically significant rise in regurgitation or aspiration events remains highly inconsistent

Moreover, the combined GLP-1 mechanisms of weight loss and delayed carbohydrate absorption may also be the key drivers of remission of type 2 diabetes and reduced cardiovascular events found by GLP-1 analogues.

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and kidney benefits in the general population with type 2 diabetes mellitus (T2DM), evidence regarding their effects in diabetic KTRs is limited